ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Severe hemophilia B
- Less than 5 years of age
- In the investigator's judgment, the patient and/or caregiver will be compliant to study procedures
- A currently detectable FIX inhibitor. A family history of inhibitors will not exclude
the patient.
- Impaired liver function
- Impaired renal function
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Chamberry, Cedex
- Le Chesnay, Cedex
- Caen Cedex 9,
- Clermont Ferrand,
- Dijon Cedex,
- leKremlin-Bicetre,
- Lyon,
- Marseille Cedex 05,
- Montmorency,
- Montpellier Cedex 5,
- Nantes cedex 1,
- Paris,
- Paris,
- Rouen,
- Saint Priest en Jarez,
- Tours,
- Vandoeuvre Les Nancy Cedex,
- Phoenix, Arizona
- Chicago, Illinois
- Chicago, Illinois
- New Brunswick, New Jersey
- Houston, Texas
- Edmonton, Alberta
- Edmonton, Alberta
- Ottawa, Ontario
- Zagreb,
- Budapest,
- Castelfranco Veneto (TV),
- Coppito (AQ),
- Bucuresti,
- Moscow,
- Saint Petersburg,
- Belgrade,
- Nis,
- Madrid,
- Sevilla,
- Los Angeles, California
- Aurora, Colorado
- Detroit, Michigan
- New Brunswick, New Jersey
- Chapel Hill, North Carolina
- Dayton, Ohio
- Houston, Texas
- Shinjuku-ku, Tokyo
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Study Evaluating rFIX; BeneFIX in Severe Hemophilia B | |||
Official Title ICMJE | An Open-Label, Single-Arm, Safety and Efficacy Study of Recombinant Human Factor IX (rFIX; BeneFIX®) in Children Less Than 6 Years of Age With Severe Hemophilia B | |||
Brief Summary | To characterize the safety and efficacy of rFIX in children less than 6 years of age with severe hemophilia B in the setting of acute bleeding episodes, prophylaxis, and/or surgery. This study will provide an opportunity for systematic observation of treatment with rFIX in children less than 6 years of age regardless of prior FIX treatment. Younger patients exhibit a different pharmacokinetic profile and therefore may respond differently to rFIX infusions when compared with older children and adults. This evaluation will provide data from which recommendations can be made regarding rFIX dosing and treatment of these patients. Surveillance for certain observations that have been made in patients treated with rFIX in the clinical and postmarketing setting will be performed, including inhibitor development, thrombogenicity, FIX recovery/lack of effect, allergic-type manifestations, and RBC agglutination. Comparisons will be derived from published reports and communications describing experience with other FIX products and protein therapeutics in general. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 3 | |||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
Condition ICMJE | Hemophilia B | |||
Intervention ICMJE | Drug: BeneFIX | |||
Study Arms ICMJE | Not Provided | |||
Publications * | Rendo P, Smith L, Lee HY, Shafer F. Nonacog alfa: an analysis of safety data from six prospective clinical studies in different patient populations with haemophilia B treated with different therapeutic modalities. Blood Coagul Fibrinolysis. 2015 Dec;26(8):912-8. doi: 10.1097/MBC.0000000000000359. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Enrollment ICMJE | 20 | |||
Original Enrollment ICMJE | Not Provided | |||
Actual Study Completion Date ICMJE | November 2007 | |||
Primary Completion Date | Not Provided | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | up to 5 Years (Child) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | United States | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00037557 | |||
Other Study ID Numbers ICMJE | 3090A1-301 | |||
Has Data Monitoring Committee | Not Provided | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Not Provided | |||
Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Verification Date | December 2007 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |